Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$17.69 -0.4%	$18.18	$16.10 ▼ $42.47	$2.22B	0.68	2.34 million shs	2.09 million shs
GMTX Gemini Therapeutics	$51.61 +3.0%	$46.96	$1.16 ▼ $14.10	$2.24B	-0.12	189,291 shs	413,983 shs
NAMS NewAmsterdam Pharma	$17.96 -1.3%	$18.51	$14.06 ▼ $27.29	$2.02B	-0.03	699,446 shs	1.01 million shs
UPB Upstream Bio	$10.88 +2.3%	$9.54	$5.14 ▼ $29.46	$585.28M	N/A	338,281 shs	798,298 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	-0.39%	-6.05%	+1.55%	-26.72%	-55.85%
GMTX Gemini Therapeutics	0.00%	-4.97%	+0.02%	-4.12%	+15.04%
NAMS NewAmsterdam Pharma	-1.32%	-11.13%	-2.97%	-24.76%	+4.97%
UPB Upstream Bio	+2.26%	-4.23%	+21.84%	+42.78%	+1,087,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.6967 of 5 stars	4.3	3.0	0.0	4.4	3.3	2.5	0.6
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	2.9977 of 5 stars	3.5	2.0	0.0	0.0	2.6	5.0	0.0
UPB Upstream Bio	2.1101 of 5 stars	3.5	0.0	0.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.62	Moderate Buy	$40.05	126.41% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	3.00	Buy	$42.89	138.80% Upside
UPB Upstream Bio	3.00	Buy	$56.50	419.30% Upside

Current Analyst Ratings Breakdown

Latest UPB, GMTX, APLS, and NAMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NAMS NewAmsterdam Pharma	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$42.00
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00
5/22/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$49.00 ➝ $41.00
5/14/2025	APLS Apellis Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $20.00
5/9/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$75.00 ➝ $52.00
5/9/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$41.00 ➝ $23.00
5/8/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$21.00 ➝ $18.00
5/8/2025	APLS Apellis Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$28.00 ➝ $20.00

(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	2.85	N/A	N/A	$1.84 per share	9.61
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
NAMS NewAmsterdam Pharma	$45.56M	44.26	N/A	N/A	$8.20 per share	2.19
UPB Upstream Bio	$2.37M	246.93	N/A	N/A	$8.77 per share	1.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.79	N/A	N/A	N/A	-28.83%	-99.19%	-25.35%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
NAMS NewAmsterdam Pharma	-$241.60M	-$1.88	N/A	N/A	N/A	-397.45%	-37.34%	-33.45%	8/6/2025 (Estimated)
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/5/2025 (Estimated)

Latest UPB, GMTX, APLS, and NAMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/7/2025	Q1 2025	APLS Apellis Pharmaceuticals	-$0.36	-$0.74	-$0.38	-$0.74	$197.61 million	$149.90 million
5/6/2025	Q1 2025	UPB Upstream Bio	-$0.49	-$0.51	-$0.02	-$0.51	$0.71 million	$0.57 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.76	4.08	3.62
GMTX Gemini Therapeutics	N/A	71.49	71.49
NAMS NewAmsterdam Pharma	N/A	19.98	19.98
UPB Upstream Bio	N/A	47.43	47.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
GMTX Gemini Therapeutics	75.42%
NAMS NewAmsterdam Pharma	89.89%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
GMTX Gemini Therapeutics	12.90%
NAMS NewAmsterdam Pharma	20.84%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	125.68 million	117.51 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	88.87 million	Optionable
UPB Upstream Bio	38	53.79 million	46.50 million	N/A

UPB, GMTX, APLS, and NAMS Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Trading 7.8% Higher - Should You Buy?

June 20 at 1:45 PM | marketbeat.com

Upstream Bio (NASDAQ:UPB) Shares Gap Down - What's Next?

June 18 at 1:42 PM | marketbeat.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Here's What Happened

June 16, 2025 | marketbeat.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 16, 2025 | msn.com

Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress

June 15, 2025 | quiverquant.com

Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor

June 15, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Raised to Hold at Wall Street Zen

June 7, 2025 | marketbeat.com

Upstream Bio, Inc. to Present TSLP Receptor Targeting Data for Verekitug at EAACI Congress 2025

June 5, 2025 | quiverquant.com

Upstream Bio to Present Mechanistic Insights into Verekitug's Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025

June 5, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading Down 3.4% - Should You Sell?

June 4, 2025 | marketbeat.com

Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 4, 2025 | globenewswire.com

Upstream Bio (NASDAQ:UPB) Trading 10.2% Higher - Here's What Happened

June 3, 2025 | marketbeat.com

1,583,154 Shares in Upstream Bio, Inc. (NASDAQ:UPB) Purchased by Wellington Management Group LLP

June 1, 2025 | marketbeat.com

Jane Street Group LLC Takes Position in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Northern Trust Corp Makes New Investment in Upstream Bio, Inc. (NASDAQ:UPB)

May 27, 2025 | marketbeat.com

Woodline Partners LP Buys New Stake in Upstream Bio, Inc. (NASDAQ:UPB)

May 25, 2025 | marketbeat.com

VR Adviser LLC Takes $37.74 Million Position in Upstream Bio, Inc. (NASDAQ:UPB)

May 22, 2025 | marketbeat.com

Upstream Bio names new chief technology officer

May 21, 2025 | investing.com

Upstream Bio Appoints Stacy Price As CTO

May 21, 2025 | nasdaq.com

Upstream Bio, Inc. Appoints Stacy Price as Chief Technology Officer to Lead Expansion of Technical Operations

May 21, 2025 | nasdaq.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPB, GMTX, APLS, and NAMS Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$17.69 -0.07 (-0.39%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$17.68 -0.01 (-0.06%)

As of 06/20/2025 06:15 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Gemini Therapeutics NASDAQ:GMTX

$51.61 +1.52 (+3.03%)

As of 06/20/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NewAmsterdam Pharma NASDAQ:NAMS

$17.96 -0.24 (-1.32%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$18.15 +0.19 (+1.06%)

As of 06/20/2025 07:39 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Upstream Bio NASDAQ:UPB

$10.88 +0.24 (+2.26%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$10.91 +0.03 (+0.28%)

As of 06/20/2025 07:21 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time